BR112014008744A2 - preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer - Google Patents

preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer

Info

Publication number
BR112014008744A2
BR112014008744A2 BR112014008744A BR112014008744A BR112014008744A2 BR 112014008744 A2 BR112014008744 A2 BR 112014008744A2 BR 112014008744 A BR112014008744 A BR 112014008744A BR 112014008744 A BR112014008744 A BR 112014008744A BR 112014008744 A2 BR112014008744 A2 BR 112014008744A2
Authority
BR
Brazil
Prior art keywords
release preparation
prolonged release
alzheimer
delaying
onset
Prior art date
Application number
BR112014008744A
Other languages
English (en)
Portuguese (pt)
Inventor
Takenaka Kaoru
Ishii Yumiko
Murakawa Yusuke
Tanoue Yutaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014008744(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112014008744A2 publication Critical patent/BR112014008744A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014008744A 2011-10-21 2012-10-19 preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer BR112014008744A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
BR112014008744A2 true BR112014008744A2 (pt) 2017-04-18

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008744A BR112014008744A2 (pt) 2011-10-21 2012-10-19 preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG2014012025A (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
EP3070081B1 (en) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
US20150141517A1 (en) 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
AU682827B2 (en) 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
CN1802178A (zh) 2003-06-06 2006-07-12 武田药品工业株式会社 固体制剂
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CA2578474A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
EP1940403A2 (en) 2005-09-22 2008-07-09 SB Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
ES2744495T3 (es) 2006-03-30 2020-02-25 Nippon Zoki Pharmaceutical Co Preparación farmacéutica sólida
AR060663A1 (es) 2006-04-27 2008-07-02 Takeda Pharmaceutical Composicion farmaceutica solida
HRP20141008T1 (hr) 2007-02-09 2015-01-02 Alphapharm Pty Ltd Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
CA2738930C (en) 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
CN102548544B (zh) 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
AU2012205798B2 (en) * 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
IN2014DN03169A (enExample) 2015-05-22
PE20141189A1 (es) 2014-09-24
AR088398A1 (es) 2014-05-28
EA201490840A1 (ru) 2014-08-29
US9907789B2 (en) 2018-03-06
KR20140081826A (ko) 2014-07-01
WO2013058409A1 (en) 2013-04-25
IL232114A0 (en) 2014-06-30
AU2012326976A1 (en) 2014-05-29
EP2768487A1 (en) 2014-08-27
ZA201403103B (en) 2015-08-26
CN104039313A (zh) 2014-09-10
TW201323018A (zh) 2013-06-16
PH12014500856A1 (en) 2014-05-19
DOP2014000077A (es) 2014-07-15
AP2014007645A0 (en) 2014-05-31
TN2014000152A1 (en) 2015-09-30
CA2852417A1 (en) 2013-04-25
UA113858C2 (uk) 2017-03-27
CR20140213A (es) 2014-06-18
MX2014004679A (es) 2014-08-01
US20140248362A1 (en) 2014-09-04
SG10201700121YA (en) 2017-03-30
JP6093762B2 (ja) 2017-03-08
CO6960544A2 (es) 2014-05-30
UY34403A (es) 2013-05-31
AU2012326976A2 (en) 2014-06-12
JP2014530802A (ja) 2014-11-20
NZ624275A (en) 2016-09-30
ECSP14013328A (es) 2014-05-31
SG2014012025A (en) 2014-06-27
MA35717B1 (fr) 2014-12-01
AU2012326976B2 (en) 2017-08-17
CL2014000992A1 (es) 2014-09-05
EP2768487B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014008744A2 (pt) preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
HUE036755T2 (hu) Antimikrobiális vegyületek, valamint ezek elõállítása és alkalmazása
WO2013057570A3 (en) Acrylic polymer formulations
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
HUE041883T2 (hu) Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
JP2013536184A5 (enExample)
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
CO7020857A2 (es) Procedimiento para la preparación de complejos de 68ga

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.